Nusinersen for treating spinal muscular atrophy

Suggested remit

To appraise the clinical and cost effectiveness of nusinersen within its marketing authorisation for treating spinal muscular atrophy.

 

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

21 November 2016 – 19 December 2016
NICE are currently working with the company to ascertain the next steps for proposed NICE guidance.

 

Batch

52

 

ID number

1069

 

Scoping workshop

Friday 13 January 2017 (afternoon) in (London)

Please send enquiries to: michelle.adhemar@nice.org.uk

 

Consultation documents

 

Back to top

 

Ixekizumab for treating active psoriatic arthritis following inadequate response to disease-modifying anti-rheumatic drugs

Suggested remit

To appraise the clinical and cost effectiveness of ixekizumab within its marketing authorisation for treating active psoriatic arthritis in adults whose disease has not responded adequately to previous disease-modifying anti-rheumatic drug therapy.

 

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

31 May 2017 – 28 June 2017

 

Batch

55

 

ID number

1194

 

Scoping workshop

No workshop - consultation only.

Please send enquiries to: michelle.adhemar@nice.org.uk

 

Consultation documents

 

Back to top

 

Naldemedine for treating opioid-induced constipation

Suggested remit

To appraise the clinical and cost effectiveness of naldemedine within its marketing authorisation for treating opioid-induced constipation.

 

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

31 May 2017 – 28 June 2017

 

Batch

55

 

ID number

1189

 

Scoping workshop

No workshop - consultation only.

Please send enquiries to: michelle.adhemar@nice.org.uk

 

Consultation documents

 

Back to top

 

Ertugliflozin monotherapy for treating type 2 diabetes

Suggested remit

To appraise the clinical and cost effectiveness of ertugliflozin monotherapy within its marketing authorisation for treating type 2 diabetes.

 

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

30 May 2017 – 27 June 2017

 

Batch

55

 

ID number

1158

 

Scoping workshop

No workshop - consultation only.

Please send enquiries to: michelle.adhemar@nice.org.uk

 

Consultation documents

 

Back to top

 

Ertugliflozin combination therapy for treating type 2 diabetes

Suggested remit

To appraise the clinical and cost effectiveness of combination therapy with ertugliflozin within its marketing authorisation for treating type 2 diabetes.

 

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

30 May 2017 – 27 June 2017

 

Batch

55

 

ID number

1159

 

Scoping workshop

No workshop - consultation only.

Please send enquiries to: michelle.adhemar@nice.org.uk

 

Consultation documents

 

Back to top

 

Tildrakizumab for treating moderate to severe plaque psoriasis

Suggested remit

To appraise the clinical and cost effectiveness of tildrakizumab within its marketing authorisation for treating adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.

 

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

25 May 2017 – 23 June 2017

 

Batch

55

 

ID number

1060

 

Scoping workshop

No workshop - consultation only.

Please send enquiries to: michelle.adhemar@nice.org.uk

 

Consultation documents

 

Back to top

 

Erenumab for preventing migraine

Suggested remit

To appraise the clinical and cost effectiveness of erenumab within its marketing authorisation for preventing migraine.

 

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

25 May 2017 – 23 June 2017

 

Batch

55

 

ID number

1188

 

Scoping workshop

No workshop - consultation only.

Please send enquiries to: michelle.adhemar@nice.org.uk

 

Consultation documents

 

Back to top

 

Inhaled alpha-1 antitrypsin for treating emphysema

Suggested remit

To appraise the clinical and cost effectiveness of inhaled alpha-1 antitrypsin within its marketing authorisation for treating emphysema.

 

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

24 May 2017 – 22 June 2017

 

Batch

55

 

ID number

1200

 

Scoping workshop

The National Institute for Health and Care Excellence (NICE) has been asked to consider an appraisal of inhaled alpha-1 antitrypsin for treating emphysema ID1200 We have recently invited stakeholders to respond to a written consultation on the draft scope and to attend a scoping workshop for this proposed appraisal.

The company that develop Inhaled alpha-1 antitrypsin have advised NICE that they have withdrawn their marketing authorisation application for this product for this indication and plan to resubmit their application in few years after collecting additional data from a planned phase 3 study. In light of this information, the Institute will not be progressing with the scoping exercise. Consequently, the scoping workshop arranged for Friday 14 July 2017 has been cancelled.

If you have any comments or concerns please contact the project manager for this proposed appraisal Michelle Adhemar on 44 (0)20 7045 2239 or via email on michelle.adhemar@nice.org.uk.

Please send enquiries to: michelle.adhemar@nice.org.uk

 

Consultation documents

 

Back to top

 

Mepolizumab for treating eosinophilic granulomatosis with polyangiitis

Suggested remit

To appraise the clinical and cost effectiveness of mepolizumab within its marketing authorisation for treating eosinophilic granulomatosis with polyangiitis.

 

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

17 May – 15 June 2017

 

Batch

55

 

ID number

1186

 

Scoping workshop

Wednesday 5 July 2017 (morning) in (London)

Please send enquiries to: michelle.adhemar@nice.org.uk

 

Consultation documents

 

Back to top

 

Epoetin alfa for treating anaemia in people with myelodysplastic syndromes

Suggested remit

To appraise the clinical and cost effectiveness of epoetin alfa within its marketing authorisation for treating anaemia in people with myelodysplastic syndromes.

 

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

17 May – 15 June 2017

 

Batch

55

 

ID number

1035

 

Scoping workshop

Wednesday 5 July 2017 (afternoon) in (London)

Please send enquiries to: michelle.adhemar@nice.org.uk

 

Consultation documents

 

Back to top

 

Caplacizumab for treating acute acquired thrombotic thrombocytopenic purpura

Suggested remit

To appraise the clinical and cost effectiveness of caplacizumab marketing authorisation for treating acute acquired thrombotic thrombocytopenic purpura.

 

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

16 May – 14 June 2017

 

Batch

55

 

ID number

1185

 

Scoping workshop

Tuesday 4 July 2017 (afternoon) in (London)

Please send enquiries to: michelle.adhemar@nice.org.uk

 

Consultation documents

 

Back to top

 

Pembrolizumab for previously treated metastatic gastric or gastro-oesophageal junction cancer

Suggested remit

To appraise the clinical and cost effectiveness of pembrolizumab within its marketing authorisation for treating previously treated metastatic gastric or gastro-oesophageal junction cancer.

 

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

3 May – 1 June 2017

 

Batch

B53

 

ID number

1168

 

Scoping workshop

No workshop - consultation only

Please send enquiries to: samantha.shannon@nice.org.uk

 

Consultation documents

 

Back to top

 

Plitidepsin in combination with dexamethasone for treating relapsed or refractory multiple myeloma

Suggested remit

To appraise the clinical and cost effectiveness of plitidepsin in combination with dexamethasone within its marketing authorisation for treating relapsed or refractory multiple myeloma.

 

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

20 April – 19 May 2017

 

Batch

B53

 

ID number

1081

 

Scoping workshop

No workshop - consultation only

Please send enquiries to: michelle.adhemar@nice.org.uk

 

Consultation documents

 

Back to top

 

Gemtuzumab ozogamacin for untreated acute myeloid leukaemia

Suggested remit

To appraise the clinical and cost effectiveness of gemtuzumab ozogamacin within its marketing authorisation for untreated acute myeloid leukaemia.

 

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

12 April – 15 May 2017

 

Batch

B53

 

ID number

982

 

Scoping workshop

No workshop - consultation only

Please send enquiries to: samantha.shannon@nice.org.uk

 

Consultation documents

 

Back to top

 

ATIR101 with haematopoietic stem cell transplantation for haematological cancers

Suggested remit

To appraise the clinical and cost effectiveness of ATIR101 as an adjunct to haematopoietic stem cell transplantation within its marketing authorisation for haematological cancers.

 

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

23 March – 21 April 2017

 

Batch

54

 

ID number

1093

 

Scoping workshop

Friday 12 May 2017 (afternoon) in (London)

Please send enquiries to: michelle.adhemar@nice.org.uk

 

Consultation documents

 

Back to top

 

Exploratory work of bevacizumab in eye conditions

Background

In 2010 the Department of Health asked NICE to explore with stakeholders what value NICE can add in advising the NHS on the clinical and cost effectiveness of Avastin (bevacizumab) to treat wet age-related macular degeneration, the leading cause of blindness in the UK, and other conditions affecting the eye.

 

Consultation on briefing document and provisional list of stakeholders

02 June 2010 – 30 June 2010

 
 

Exploratory workshop

13 July 2010 in Manchester

 

Back to top